We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · October 27, 2020

Everolimus + Bevacizumab Is an Effective First-Line Treatment for Advanced Papillary Variant RCC



Additional Info

Everolimus Plus Bevacizumab Is an Effective First-Line Treatment for Patients With Advanced Papillary Variant Renal Cell Carcinoma: Final Results From a Phase II Trial
Cancer 2020 Sep 25;[EPub Ahead of Print], DR Feldman, Y Ged, CH Lee, A Knezevic, AM Molina, YB Chen, J Chaim, DT Coskey, S Murray, SK Tickoo, VE Reuter, S Patil, H Xiao, J Aghalar, AJ Apollo, MI Carlo, RJ Motzer, MH Voss

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading